Exclusive Summary

• Certified by both US-FDA and UK-MHRA and already registered in the US, providing supreme quality endorsement that enables immediate commercialization in regulated markets and fast-track registration via CPPs in emerging markets.
• Recognized by the WHO Essential Medicines List as a first-line therapy for neuropathic pain, Pregabalin targets a massive global population of over 500 million patients with constant and growing prescription demand.
• Offering the 75mg (initiation/titration) and 300mg (maximum/maintenance) core clinical strengths combined with scalable Chinese manufacturing guarantees highly competitive pricing and lucrative profit margins for global distributors.